Orforglipron Research for Type 2 Diabetes
An evidence-based overview of research examining Orforglipron in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
ATTAIN-2 evaluated orforglipron in adults with obesity and type 2 diabetes, showing HbA1c reductions of 1.66% with the 36mg dose and 75.5% of participants achieving HbA1c <7%. The oral administration without food restrictions offers practical advantages over existing therapies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Orforglipron may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.